MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Kodu・Aktsiate loetelu・uniQure NV

uniQure NV

Suletud

59.92 3.51

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

56.08

Max

61.72

Põhinäitajad
By Trading Economics
Sissetulek	5.9M -38M
Müük	3.7M 5.3M
Kasumimarginaal	-716.819
Töötajad	209
EBITDA	-4.5M -44M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+28.63% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. nov 2025

Turustatistika
By TradingEconomics
Turukapital	2.4B 3.3B
Eelmine avamishind	56.41
Eelmine sulgemishind	59.92

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

10.05 / 14.75 Toetus ja vastupanu

uniQure NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2024, 15:18 UTC

Suurimad hinnamuutused turgudel

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

24. sept 2025, 18:51 UTC

Tulu

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

uniQure NV Prognoos

Hinnasiht

By TipRanks

28.63% tõus

12 kuu keskmine prognoos

Keskmine 74.5 USD 28.63%

Kõrge 110 USD

Madal 55 USD

Põhineb 12 Wall Streeti analüütiku instrumendi uniQure NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi uniQure NV aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

10.05 / 14.75Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.